HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA First Amendment Federal Register Notice Needs Clarification – Sen. Reed

This article was originally published in The Tan Sheet

Executive Summary

FDA should clarify the Federal Register notice in which it asks for comments on its application of the First Amendment by issuing a second notice and extending the comment deadline, Sen. Jack Reed (D-R.I.) says in a July 16 letter to the agency

You may also be interested in...



OTC Tax Deductibility Could Gain Favor In 108th Congress

CHPA believes the Republican majority in the Senate will be more willing to consider the association's proposal to make OTC drug purchases tax deductible

Supplement Claims Rules v. Drugs, Foods: FDA Opens Free Speech Debate

FDA invites public comments on the constitutionality of its approach to regulating claims for dietary supplements compared with Rx drugs and foods in a notice appearing in the May 16 Federal Register

Dietary supplement labels commission to be chaired by Cornell professor Nesheim.

DIETARY SUPPLEMENT COMMISSION TO BE CHAIRED BY CORNELL'S NESHEIM, the White House announced Oct. 2. Malden Nesheim, PhD, professor of nutrition at Cornell University, will head the seven-member commission established under the Dietary Supplement Health & Education Act of 1994 to generate recommendations for regulations and legislation related to label claims for dietary supplements.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel